Related references
Note: Only part of the references are listed.Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Sho Iketani et al.
NATURE (2023)
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
Michihito Sasaki et al.
SCIENCE TRANSLATIONAL MEDICINE (2023)
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis
Wen Wen et al.
ANNALS OF MEDICINE (2022)
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
Laura Vangeel et al.
ANTIVIRAL RESEARCH (2022)
A Patent Review on SARS Coronavirus Main Protease (3CLpro) Inhibitors
C. S. Brian Chia et al.
CHEMMEDCHEM (2022)
Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance
Jacqueto Zephyr et al.
JOURNAL OF MOLECULAR BIOLOGY (2022)
Synthon-based ligand discovery in virtual libraries of over 11 billion compounds
Arman A. Sadybekov et al.
NATURE (2022)
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
Huiping Shuai et al.
NATURE (2022)
A tale of two antiviral targets - and the COVID-19 drugs that bind them
Megan Cully
NATURE REVIEWS DRUG DISCOVERY (2022)
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Jennifer Hammond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
MANORAA: A machine learning platform to guide protein-ligand design by anchors and influential distances
Duangrudee Tanramluk et al.
STRUCTURE (2022)
The changing epidemiology of human monkeypox—A potential threat? A systematic review
Eveline M. Bunge et al.
PLoS Neglected Tropical Diseases (2022)
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
E. Wesley Ely et al.
LANCET RESPIRATORY MEDICINE (2022)
Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
Zongyang Lv et al.
FRONTIERS IN CHEMISTRY (2022)
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions
Catia Marzolini et al.
ANNALS OF INTERNAL MEDICINE (2022)
Machine learning approaches and their applications in drug discovery and design
Sonal Priya et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2022)
Nirmatrelvir Plus Ritonavir: First Approval
Yvette N. Lamb
DRUGS (2022)
Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLPro)
Sang Hoon Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants
Samantha E. Greasley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2022)
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CLProtease Inhibitor Clinical Candidate for Treating COVID-19
Yuto Unoh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
The HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release
Caroline O. Tabler et al.
JOURNAL OF VIROLOGY (2022)
An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy
Antonio Merolli et al.
SCIENTIFIC REPORTS (2022)
The future of Paxlovid for COVID-19
Talha Burki
LANCET RESPIRATORY MEDICINE (2022)
Application of Computational Biology and Artificial Intelligence in Drug Design
Yue Zhang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid
Rita Rubin
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal
Eleonora Proia et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2022)
COVID-19 Rebound associated with nirmatrelvir/ritonavir pre-hospital therapy
J. M. Coulson et al.
JOURNAL OF INFECTION (2022)
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance
Ala M. Shaqra et al.
NATURE COMMUNICATIONS (2022)
Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
Olaf Isken et al.
PLOS PATHOGENS (2022)
Current Effective Therapeutics in Management of COVID-19
Kavya Atluri et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
Ju Hwan Jeong et al.
ANTIVIRAL RESEARCH (2022)
Corona versus Dengue: Distinct Mechanisms for Inhibition of Polyprotein Processing by Antiviral Drugs
Mira A. M. Behnam et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu-Chyi Hwang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2022)
Association Between the Use of Antibiotics, Antivirals, and Hospitalizations Among Patients With Laboratory-confirmed Influenza
S. Scott Sutton et al.
CLINICAL INFECTIOUS DISEASES (2021)
Dancing with Trojan horses: an interplay between the extracellular vesicles and viruses
Raied A. Badierah et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2021)
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action
Hassan Yousefi et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
Young Joo Park et al.
GUT AND LIVER (2021)
SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
Wioletta Rut et al.
NATURE CHEMICAL BIOLOGY (2021)
Immunological approaches to HIV cure
Adam R. Ward et al.
SEMINARS IN IMMUNOLOGY (2021)
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond
Ashley N. Matthew et al.
CHEMICAL REVIEWS (2021)
On track to tackle dengue: History and future of NS4B ligands
Mira A. M. Behnam et al.
CELL HOST & MICROBE (2021)
Structural insights into SARS-CoV-2 proteins
Rimanshee Arya et al.
JOURNAL OF MOLECULAR BIOLOGY (2021)
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
Vicky Mody et al.
COMMUNICATIONS BIOLOGY (2021)
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
Joseph Heskin et al.
LANCET (2021)
Immune reactivity during COVID-19: Implications for treatment
Claudio Napoli et al.
IMMUNOLOGY LETTERS (2021)
A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction
Suzanne J. F. Kaptein et al.
NATURE (2021)
A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis
Ravindra M. Mehta et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Synthesis, Structure-Activity Relationships, and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease
Shenyou Nie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
Jeremy D. Baker et al.
PLOS ONE (2021)
Antiviral pills could change pandemic’s course
Jennifer Couzin-Frankel
SCIENCE (2021)
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen et al.
SCIENCE (2021)
CARD8 is an inflammasome sensor for HIV-1 protease activity
Qiankun Wang et al.
SCIENCE (2021)
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
Jerzy Osipiuk et al.
NATURE COMMUNICATIONS (2021)
Precursors of Viral Proteases as Distinct Drug Targets
Tatana Majerova et al.
VIRUSES-BASEL (2021)
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Britton Boras et al.
NATURE COMMUNICATIONS (2021)
Broad-Spectrum Antiviral Peptides and Polymers
Agnes Kuroki et al.
ADVANCED HEALTHCARE MATERIALS (2021)
Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome
Isabel Pablos et al.
CELL REPORTS (2021)
Antiviral nucleoside analogs
Vladimir E. Kataev et al.
CHEMISTRY OF HETEROCYCLIC COMPOUNDS (2021)
Running With Scissors: Evolutionary Conflicts Between Viral Proteases and the Host Immune System
Brian V. Tsu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Kaposi's Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
Romain Palich et al.
CANCERS (2021)
Small Extracellular Vesicles and COVID19-Using the Trojan Horse to Tackle the Giant
Blanka Maria Borowiec et al.
CELLS (2021)
Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients
Matthew Weichseldorfer et al.
PHARMACEUTICS (2021)
β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
Shuntai Zhou et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure
Damir Garcia-Cehic et al.
JOURNAL OF VIRAL HEPATITIS (2021)
Unconventional viral gene expression mechanisms as therapeutic targets
Jessica Sook Yuin Ho et al.
NATURE (2021)
Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases
Rita M. Meganck et al.
NATURE MEDICINE (2021)
The human virome: assembly, composition and host interactions
Guanxiang Liang et al.
NATURE REVIEWS MICROBIOLOGY (2021)
Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome
Pramod R. Bhatt et al.
SCIENCE (2021)
Hepatitis C Viral Replication Complex
Hui-Chun Li et al.
VIRUSES-BASEL (2021)
Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture
Khushboo Bafna et al.
CELL REPORTS (2021)
Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors
Dario Akaberi et al.
ANTIVIRAL RESEARCH (2021)
Amino Acid and Peptide-Based Antiviral Agents
Andrzej S. Skwarecki et al.
CHEMMEDCHEM (2021)
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Yaseen M. Arabi et al.
INTENSIVE CARE MEDICINE (2021)
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Florian Kabinger et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)
Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies
Lee A. Armstrong et al.
PLOS ONE (2021)
Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme
Chang Liu et al.
SCIENCE (2021)
HIV-1 Genomes Are Enriched in Memory CD4+ T-Cells with Short Half-Lives
Vincent Morcilla et al.
MBIO (2021)
In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex
Ivonne Buitron-Gonzalez et al.
RESULTS IN CHEMISTRY (2021)
Novel dynamic residue network analysis approaches to study allosteric modulation: SARS-CoV-2 Mpro and its evolutionary mutations as a case study
Olivier Sheik Amamuddy et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed de novo design model
Aaron Morris et al.
CHEMICAL COMMUNICATIONS (2021)
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics
Rick Oerlemans et al.
RSC MEDICINAL CHEMISTRY (2021)
A review: Mechanism of action of antiviral drugs
Shamaila Kausar et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2021)
Coronavirus biology and replication: implications for SARS-CoV-2
Philip V'kovski et al.
NATURE REVIEWS MICROBIOLOGY (2021)
Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance
Thomas R. Weikl et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2020)
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China
David S. Hui et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Emmie de Wit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century
Vivaldo Gomes da Costa et al.
ARCHIVES OF VIROLOGY (2020)
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
Linlin Zhang et al.
SCIENCE (2020)
Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model
Mart Toots et al.
TRANSLATIONAL RESEARCH (2020)
Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors
Ashley N. Matthew et al.
MBIO (2020)
Seasonal and pandemic influenza: 100 years of progress, still much to learn
Jake Dunning et al.
MUCOSAL IMMUNOLOGY (2020)
The continued threat of emerging flaviviruses
Theodore C. Pierson et al.
NATURE MICROBIOLOGY (2020)
Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma
Dominika Fassmannova et al.
CANCERS (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus
Fanny Georgi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
Chunlong Ma et al.
CELL RESEARCH (2020)
Allosteric Inhibition of the SARS-CoV-2 Main Protease: Insights from Mass Spectrometry Based Assays
Tarick J. El-Baba et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
The GABA(B)Receptor-Structure, Ligand Binding and Drug Development
Linn Samira Mari Evenseth et al.
MOLECULES (2020)
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Brandi N. Williamson et al.
NATURE (2020)
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
Donghyuk Shin et al.
NATURE (2020)
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
Theresa Klemm et al.
EMBO JOURNAL (2020)
Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy
Miao Miao et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
Robert L. Hoffman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
MAKING SENSE OF CORONAVIRUS MUTATIONS
Ewen Callaway
NATURE (2020)
Drug repurposing approach to fight COVID-19
Thakur Uttam Singh et al.
PHARMACOLOGICAL REPORTS (2020)
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
Lifeng Fu et al.
NATURE COMMUNICATIONS (2020)
Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease
Tian-hao Zhang et al.
PLOS GENETICS (2020)
Viral Emerging Diseases: Challenges in Developing Vaccination Strategies
Maria Trovato et al.
FRONTIERS IN IMMUNOLOGY (2020)
Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design
Wioletta Rut et al.
SCIENCE ADVANCES (2020)
Evolution of drug resistance in HIV protease
Dhara Shah et al.
BMC BIOINFORMATICS (2020)
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site
Jaeyong Lee et al.
NATURE COMMUNICATIONS (2020)
CRISPR based editing of SIV proviral DNA in ART treated non-human primates
Pietro Mancuso et al.
NATURE COMMUNICATIONS (2020)
The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir
Mahbuba R. Subeha et al.
CANCERS (2020)
Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors
Yuan Gu et al.
CELLULAR SIGNALLING (2020)
Inhibition and induction of CYP enzymes in humans: an update
Jukka Hakkola et al.
ARCHIVES OF TOXICOLOGY (2020)
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
Marie Lecronier et al.
CRITICAL CARE (2020)
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®
James G. Taylor et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Exploiting the unique features of Zika and Dengue proteases for inhibitor design
Tatana Majerova et al.
BIOCHIMIE (2019)
Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice
Chenglai Xia et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
The remarkable history of the hepatitis C virus
Stanislas Pol et al.
GENES AND IMMUNITY (2019)
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis
Chun-Hsien Chen et al.
SCIENTIFIC REPORTS (2019)
NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal
Benjamin Trinite et al.
RETROVIROLOGY (2019)
Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice
Prasanta K. Dash et al.
NATURE COMMUNICATIONS (2019)
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
Thomas G. Cotter et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Virtual Screening Techniques in Drug Discovery: Review and Recent Applications
Sheisi F. L. da Silva Rocha et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naive subjects
Bin Han et al.
ANTIVIRAL RESEARCH (2019)
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
Mart Toots et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection
Federico J. Mensa et al.
FUTURE MICROBIOLOGY (2019)
Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective
Thitiya Boonma et al.
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2019)
Expression of novel proteins by polyomaviruses and recent advances in the structural and functional features of agnoprotein of JC virus, BK virus, and simian virus 40
A. Sami Saribas et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Prisoners of war - host adaptation and its constraints on virus evolution
Peter Simmonds et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
Nathalie Alazard-Dany et al.
VIRUSES-BASEL (2019)
Current and future priorities for the development of optimal HIV drugs
Marco Vitoria et al.
CURRENT OPINION IN HIV AND AIDS (2019)
Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment
Liangqun Huang et al.
SCIENTIFIC REPORTS (2019)
Bayesian semi-supervised learning for uncertainty-calibrated prediction of molecular properties and active learning
Yao Zhang et al.
CHEMICAL SCIENCE (2019)
Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?
Leigh Cervino et al.
ANNALS OF PHARMACOTHERAPY (2018)
Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein
Jian Lei et al.
ANTIVIRAL RESEARCH (2018)
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
Maria C. Sorbo et al.
DRUG RESISTANCE UPDATES (2018)
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C
Young-A Heo et al.
DRUGS (2018)
The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies
Giovanni Barillari et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Treatment of hepatitis C: Results in real life
Christophe Hezode
LIVER INTERNATIONAL (2018)
Multi-spectroscopic and molecular modeling approaches to elucidate the binding interaction between bovine serum albumin and darunavir, a HIV protease inhibitor
Jie-Hua Shi et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2018)
Nelfinavir Induces Endoplasmic Reticulum Stress and Sensitizes Renal Cancer Cells to TRAIL
Kazuki Okubo et al.
ANTICANCER RESEARCH (2018)
Danoprevir: First Global Approval
Anthony Markham et al.
DRUGS (2018)
Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure
Raza M. Alvi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Targeting intramolecular proteinase NS2B/3 cleavages for trans-dominant inhibition of dengue virus
David A. Constant et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation
Jana Humpolickova et al.
SCIENTIFIC REPORTS (2018)
Analysis of drug resistance in HIV protease
Shrikant D. Pawar et al.
BMC BIOINFORMATICS (2018)
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ira M. Jacobson et al.
GASTROENTEROLOGY (2017)
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
Ira M. Jacobson et al.
GASTROENTEROLOGY (2017)
Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus
Eric Lawitz et al.
HEPATOLOGY (2017)
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study
Chih-Wei Lin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Zika Virus Protease: An Antiviral Drug Target
CongBao Kang et al.
TRENDS IN MICROBIOLOGY (2017)
The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review
Sheila V. Graham
CLINICAL SCIENCE (2017)
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
Eric J. Lawitz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir plus Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV
Sammy Saab et al.
LIVER INTERNATIONAL (2016)
Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme
Joon H. Park et al.
BIOCHEMISTRY (2016)
Fragment-Based Protein-Protein Interaction Antagonists of a Viral Dimeric Protease
Jonathan E. Gable et al.
CHEMMEDCHEM (2016)
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy
L. B. Dustin et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Approved Antiviral Drugs over the Past 50 Years
Erik De Clercq et al.
CLINICAL MICROBIOLOGY REVIEWS (2016)
Elbasvir/Grazoprevir: First Global Approval
Gillian M. Keating
DRUGS (2016)
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis
Edward Gane et al.
GASTROENTEROLOGY (2016)
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naive or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Edward J. Gane et al.
GASTROENTEROLOGY (2016)
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Eric Lawitz et al.
GASTROENTEROLOGY (2016)
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial
Edward J. Gane et al.
GASTROENTEROLOGY (2016)
Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
Srini Ramanathan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
Arun K. Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study
M. Rodriguez-Torres et al.
JOURNAL OF VIRAL HEPATITIS (2016)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor
Jian Lei et al.
SCIENCE (2016)
A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda
Francois Blanquart et al.
ELIFE (2016)
Highly heterogeneous mutation rates in the hepatitis C virus genome
Ron Geller et al.
NATURE MICROBIOLOGY (2016)
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
Stefan Zeuzem et al.
ANNALS OF INTERNAL MEDICINE (2015)
Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
Preethi Krishnan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development
Dahai Luo et al.
ANTIVIRAL RESEARCH (2015)
The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future
Alice Tseng et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection
Elizabeth M. Sherman et al.
CLINICAL THERAPEUTICS (2015)
Highly resistant HIV-1 proteases and strategies for their inhibition
Irene T. Weber et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort
Samantha J. Shepherd et al.
JOURNAL OF CLINICAL VIROLOGY (2015)
Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET
Stuart C. Gordon et al.
JOURNAL OF HEPATOLOGY (2015)
Applications of Fluorine in Medicinal Chemistry
Eric P. Gillis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Retroviral proteases and their roles in virion maturation
Jan Konvalinka et al.
VIROLOGY (2015)
Induction of Suicidal Erythrocyte Death by Nelfinavir
Rosi Bissinger et al.
TOXINS (2015)
Thermodynamic and structural analysis of HIV protease resistance to darunavir - analysis of heavily mutated patient- derived HIV-1 proteases
Milan Kozisek et al.
FEBS JOURNAL (2014)
Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource
Donald B. Smith et al.
HEPATOLOGY (2014)
Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
Asa Rosenquist et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Nelfinavir Inhibits Maturation and Export of Herpes Simplex Virus 1
Nene N. Kalu et al.
JOURNAL OF VIROLOGY (2014)
Induced Maturation of Human Immunodeficiency Virus
Simone Mattei et al.
JOURNAL OF VIROLOGY (2014)
Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir
Hironori Hayashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
In Vitro Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir
Min Jiang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Temporal Response of the Human Virome to Immunosuppression and Antiviral Therapy
Iwijn De Vlaminck et al.
CELL (2013)
Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases
Chi-Pang Chuck et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Simeprevir for the treatment of chronic hepatitis C
David M. You et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
Eric Lawitz et al.
JOURNAL OF HEPATOLOGY (2013)
Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease
Jon Jacobs et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Efavirenz Enhances HIV-1 Gag Processing at the Plasma Membrane through Gag-Pol Dimerization
Sho Sudo et al.
JOURNAL OF VIROLOGY (2013)
Nelfinavir Inhibits Intra-Mitochondrial Calcium Influx and Protects Brain against Hypoxic-Ischemic Injury in Neonatal Mice
Irina V. Utkina-Sosunova et al.
PLOS ONE (2013)
Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against the Initial Autocleavage in Gag-Pol Polyprotein Processing
David A. Davis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
Vincenzo Summa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Mutations in HIV-1 gag and pol Compensate for the Loss of Viral Fitness Caused by a Highly Mutated Protease
Milan Kozisek et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir
Kristen M. Marks et al.
ANTIVIRAL THERAPY (2012)
Activity, Specificity, and Probe Design for the Smallpox Virus Protease K7L
Alexander E. Aleshin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells
Lihua Sun et al.
JOURNAL OF CHEMOTHERAPY (2012)
Antiviral strategies in hepatitis C virus infection
Christoph Sarrazin et al.
JOURNAL OF HEPATOLOGY (2012)
Loss of the Protease Dimerization Inhibition Activity of Tipranavir (TPV) and Its Association with the Acquisition of Resistance to TPV by HIV-1
Manabu Aoki et al.
JOURNAL OF VIROLOGY (2012)
Placement of Leucine Zipper Motifs at the Carboxyl Terminus of HIV-1 Protease Significantly Reduces Virion Production
Yen-Yu Pan et al.
PLOS ONE (2012)
Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections
Srikanth Venkatraman
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans
Sander van Boheemen et al.
MBIO (2012)
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
S. Kawabata et al.
CELL DEATH & DISEASE (2012)
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
Steven Harper et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate
Ruy M. Ribeiro et al.
PLOS PATHOGENS (2012)
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection
Richard Elion et al.
AIDS (2011)
Two drugs approved for chronic hepatitis C infection
Kate Traynor
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2011)
Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C
Bryce S. Foote et al.
ANNALS OF PHARMACOTHERAPY (2011)
Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions
Ingeborg Zehbe et al.
ANTIVIRAL RESEARCH (2011)
Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells
Gavin Batman et al.
ANTIVIRAL THERAPY (2011)
TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
Ira M. Jacobson et al.
GASTROENTEROLOGY (2011)
Lopinavir/Ritonavir Resistance in Patients Infected With HIV-1: Two Divergent Resistance Pathways?
Karen Champenois et al.
JOURNAL OF MEDICAL VIROLOGY (2011)
Accessory Mutations Maintain Stability in Drug-Resistant HIV-1 Protease
Max W. Chang et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Enzyme Inhibition by Allosteric Capture of an Inactive Conformation
Gregory M. Lee et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
Ann D. Kwong et al.
NATURE BIOTECHNOLOGY (2011)
Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors
John M. Louis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Coronaviruses An RNA proofreading machine regulates replication fidelity and diversity
Mark R. Denison et al.
RNA BIOLOGY (2011)
Origins of HIV and the AIDS Pandemic
Paul M. Sharp et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2011)
Pegylated interferon and ribavirin treatment for hepatitis C virus infection
Emilio Palumbo
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2011)
Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or-2b to Patients With Chronic Hepatitis C
Patrick Marcellin et al.
GASTROENTEROLOGY (2011)
Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease
X. Tong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
Annemarie M. J. Wensing et al.
ANTIVIRAL RESEARCH (2010)
Clinical management of HIV-1 resistance
Roger Paredes et al.
ANTIVIRAL RESEARCH (2010)
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Samuel Broder
ANTIVIRAL RESEARCH (2010)
Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
Henk W. Reesink et al.
GASTROENTEROLOGY (2010)
HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS
Wu Deng et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug Resistance
Madhavi N. L. Nalam et al.
JOURNAL OF VIROLOGY (2010)
Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
Dirk Jochmans et al.
RETROVIROLOGY (2010)
Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor
Ashok Arasappan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
THERAPEUTIC TARGETS FOR INFLUENZA - PERSPECTIVES IN DRUG DEVELOPMENT
Tatana Majerova et al.
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS (2010)
Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells
Ansgar Bruning et al.
BREAST CANCER RESEARCH (2010)
In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor
Tse-I Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors
Manabu Aoki et al.
JOURNAL OF VIROLOGY (2009)
Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
Jose M. Cuevas et al.
JOURNAL OF VIROLOGY (2009)
Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir
Klara Grantz Saskova et al.
JOURNAL OF VIROLOGY (2009)
Current and Novel Inhibitors of HIV Protease
Jana Pokorna et al.
VIRUSES-BASEL (2009)
Challenges in modern drug discovery: A case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection
F. George Njoroge et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
Scott D. Seiwert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy
Joell J. Gills et al.
AUTOPHAGY (2008)
Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350
Pierre Raboisson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034
Vincent Madison et al.
JOURNAL OF SYNCHROTRON RADIATION (2008)
A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
Kiira Ratia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir
Klara Grantz Saskova et al.
PROTEIN SCIENCE (2008)
Toxicity of HIV protease inhibitors: clinical considerations
Christoph Boesecke et al.
CURRENT OPINION IN HIV AND AIDS (2008)
Atazanavir/ritonavir: A review of its use in HIV therapy
Nils von Hentig
DRUGS OF TODAY (2008)
Design of HIV protease inhibitors targeting protein backbone: An effective strategy for combating drug resistance
Arun K. Ghosh et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
Arun K. Ghosh et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Molecular analysis of the HIV-1 resistance development:: Enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants
Milan Kozisek et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics
Robert B. Perni et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Discovery of the HCVNS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II.: Key steps in structure-based optimization
Andrew J. Prongay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism
Monique Nijhuis et al.
PLOS MEDICINE (2007)
Clinical pharmacokinetics of darunavir
Michael Rittweger et al.
CLINICAL PHARMACOKINETICS (2007)
Discovery of (1R, 5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:: A potential therapeutic agent for the treatment of hepatitis C infection
Srikanth Venkatraman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1
Warren A. Chow et al.
ANTI-CANCER DRUGS (2006)
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
Xiao Tong et al.
ANTIVIRAL RESEARCH (2006)
Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants
T Majerová-Uhlíková et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance
C de Mendoza et al.
AIDS (2006)
Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus
P Erbel et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Fosamprenavir - Clinical pharmacokinetics and drug interactions of the amprenavir prodrug
MB Wire et al.
CLINICAL PHARMACOKINETICS (2006)
Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir
L Doyon et al.
ANTIVIRAL RESEARCH (2005)
Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease
SC Pettit et al.
JOURNAL OF VIROLOGY (2005)
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors
V Svicher et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 - Structural analysis indicates different resistance mechanisms
C Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Inhibitors of hepatitis C virus NS3•4A protease.: Part 3:: P2 proline variants
RB Perni et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Inhibitors of hepatitis C virus NS3•4A protease 2.: Warhead SAR and optimization
RB Perni et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections
GA Pankey et al.
CLINICAL INFECTIOUS DISEASES (2004)
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir
ES Furfine et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients
AG Marcelin et al.
JOURNAL OF MEDICAL VIROLOGY (2004)
Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism
SC Pettit et al.
JOURNAL OF VIROLOGY (2004)
Atazanavir for the treatment of human immunodeficiency virus infection
AJ Busti et al.
PHARMACOTHERAPY (2004)
Herpesvirus protease inhibition by dimer disruption
N Shimba et al.
JOURNAL OF VIROLOGY (2004)
Antiviral drugs in current clinical use
E De Clercq
JOURNAL OF CLINICAL VIROLOGY (2004)
Inhibitors of hepatitis C virus NS3•4A protease 1.: Non-charged tetrapeptide variants
RB Perni et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Novel bis-tetrahydrofuranylurethane-containin nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro
Y Koh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
HIV protease inhibitors acutely impair glucose-stimulated insulin release
JC Koster et al.
DIABETES (2003)
Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease
R Khayat et al.
BIOCHEMISTRY (2003)
Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance
S Spira et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage
SC Pettit et al.
JOURNAL OF VIROLOGY (2003)
Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains
J Weber et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
Atazanavir: a novel HIV-1 protease inhibitor
PJ Piliero
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2002)
Recent advances in the molecular biology of Hepatitis C virus
S Rosenberg
JOURNAL OF MOLECULAR BIOLOGY (2001)
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
DJ Kempf et al.
JOURNAL OF VIROLOGY (2001)
Initial sequencing and analysis of the human genome
ES Lander et al.
NATURE (2001)
Genetic risks of antiviral nucleoside analogues - a survey
P Wutzler et al.
ANTIVIRAL RESEARCH (2001)
Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity
M Shehu-Xhilaga et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
